Board of Scientific Counselors, National Center for Injury Prevention and Control, (BSC, NCIPC), 1191-1192 [2016-265]
Download as PDF
<![CDATA[
1191
Federal Register / Vol. 81, No. 6 / Monday, January 11, 2016 / Notices
allow us to continue to assess the
effectiveness of the CDC-developed
comprehensive approach to TDV for
longer-term follow-up as the students in
our sample age and their engagement in
dating relationships increases. The
current evaluation of Dating Matters®
tests a comprehensive approach to
prevent TDV among youth in high-risk
urban communities. In order to address
gaps in effective prevention
programming for youth in urban
communities with high crime and
economic disadvantage, who may be at
highest risk for TDV perpetration and
victimization, Dating Matters® focuses
on middle school youth with universal
primary prevention strategies aimed at
building a foundation of healthy
relationship skills before dating and/or
TDV is initiated.
All data collected as part of this
request will be used in the longitudinal
outcome evaluation of the Dating
Matters® initiative. No teen dating
violence comprehensive program has
been developed and implemented
specifically for high risk urban
communities. Further, no other data
source exists to examine the
effectiveness of the Dating Matters®
initiative for preventing dating violence.
The evaluation utilizes a cluster
randomized design in which 46 schools
in four funded communities (Alameda
County, California; Baltimore,
Maryland; Broward County, Florida;
and, Chicago, Illinois), were randomized
to either Dating Matters® or standard
practice.
CDC seeks to continue evaluation
activities in these four communities.
Therefore, this data collection is critical
to understand the effectiveness,
feasibility, and cost of Dating Matters®
and to inform decisions about
disseminating the program to other
communities.
OMB approval is requested for three
years for this revision. The only cost to
respondents will be time spent on
responding to the survey. A total of
4,399 respondents will be approached
on an annual basis with an average
estimated burden of 45/60 minutes per
respondent per year (3,299 burden
hours).
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondent
Form name
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(hours)
Student Program Participant ...........................
Student Outcome Survey Follow-up ..............
4,399
1
45/60
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2016–287 Filed 1–8–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
mstockstill on DSK4VPTVN1PROD with NOTICES
Board of Scientific Counselors,
National Center for Injury Prevention
and Control, (BSC, NCIPC)
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces, the following meeting of the
aforementioned committee:
Time and Date: 9:00 a.m.–3:00 p.m.,
EST, January 28, 2016 (OPEN).
Public Comment Time and Date: 1:00
p.m.–2:30 p.m.*, EST, January 28, 2016.
* Please note that the public comment
period ends at the time indicated above
or following the last call for comments,
whichever is earlier. Members of the
public who want to submit comments
must pre-register by January 18, 2016 to
opioidsguidelines@cdc.gov. All requests
must contain the name, address, email
address, organizational affiliation of the
speaker, and the topic being addressed
VerDate Sep<11>2014
18:17 Jan 08, 2016
Jkt 238001
with accompanying written comments.
Written comments should be limited to
one page single spaced with 1 inch
margins.
Members of the public must indicate
at pre-registration whether they would
like to deliver oral remarks in addition
to written comment. Comments may be
delivered in person or by phone and
will be assigned on a first come-first
served basis until all time slots are
filled. Speakers providing public
comment must call in or be present at
the beginning of the public comment
period. All public comments will be
limited to two minutes per speaker.
Since the number of time slots is
limited, it is requested that each
organization register one speaker to
represent their organization. Both oral
and written comments will be included
in the official record of the meeting.
Place: Centers for Disease Control and
Prevention, Building 21, Auditorium B–
3, 1600 Clifton Road NE., Atlanta, GA
30329.
Audio Conference toll-free dial-in
Number: 1–888–469–1243, Participant
Code: 4709506, TTY accessible link:
https://www.captionedtext.com/client/
event.aspx?CustomerID=1891&EventID=
2812716.
CDC encourages participation by
persons with disabilities. Captions and
participation by persons with
communications challenges will be
available online via Relay Conference
Captioning. To view the online captions
at the start time of the event, please
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
login for captioning at https://
www.captionedtext.com/client/
event.aspx?CustomerID=1891&EventID=
2812716.
Requests for accommodations,
questions, or comments on accessibility
(Section 508) compliance may be
directed to Tonia Lindley, imx9@
cdc.gov.
Status: The meeting as designated
above will be open to the public limited
only by the space available. The meeting
room will accommodate up to 200
people. See instructions above regarding
pre-registration and delivering public
comment.
Purpose: The Board will: (1) Conduct,
encourage, cooperate with, and assist
other appropriate public health
authorities, scientific institutions, and
scientists in the conduct of research,
investigations, experiments,
demonstrations, and studies relating to
the causes, diagnosis, treatment, control,
and prevention of physical and mental
diseases, and other impairments; (2)
assist States and their political
subdivisions in preventing and
suppressing communicable and noncommunicable diseases and other
preventable conditions and in
promoting health and well-being; and
(3) conduct and assist in research and
control activities related to injury.
The Board of Scientific Counselors
makes recommendations regarding
policies, strategies, objectives, and
priorities; and reviews progress toward
injury prevention goals and provides
E:\FR\FM\11JAN1.SGM
11JAN1
mstockstill on DSK4VPTVN1PROD with NOTICES
1192
Federal Register / Vol. 81, No. 6 / Monday, January 11, 2016 / Notices
evidence in injury prevention-related
research and programs. The Board also
provides advice on the appropriate
balance of intramural and extramural
research, the structure, progress and
performance of intramural programs.
The Board is designed to provide
guidance on extramural scientific
program matters, including the: (1)
Review of extramural research concepts
for funding opportunity
announcements; (2) conduct of
Secondary Peer Review of extramural
research grants, cooperative agreements,
and contracts applications received in
response to the funding opportunity
announcements as it relates to the
Center’s programmatic balance and
mission; (3) submission of secondary
review recommendations to the Center
Director of applications to be considered
for funding support; (4) review of
research portfolios, and (5) review of
program proposals.
Matters for Discussion: The Board of
Scientific Counselors will discuss the
draft recommendations in the CDC
Guideline for Prescribing Opioids for
Chronic Pain (Guideline), as well as
observations formulated in the Opioid
Guideline Workgroup Report. There will
be 90 minutes allotted for public
comments at the end of the session. See
above instructions on pre-registration
for public comment. A transcript of the
meeting and public comments received
at the meeting will be posted to the
docket at www.regulations.gov (Docket
No. CDC–2015–0112).
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Arlene Greenspan, Dr.P.H., M.P.H., P.T.
Associate Director for Science, NCIPC,
CDC, 4770 Buford Highway NE.,
Mailstop F–63, Atlanta, GA 30341,
Telephone (770) 488–4696; Email
opioidsguidelines@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Infectious Diseases, Centers for Disease
Control and Prevention (CDC).
Centers for Disease Control and
Prevention
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
Proposed Project
Background and Brief Description
Under the Public Health Service Act
(42 United States Code 264) and under
42 Code of Federal Regulations (CFR)
§ 71.32(b) and 42 CFR 70.2, CDC can
order airlines and maritime lines
operating conveyances arriving from
another country or traveling between
states to submit a record for passengers
and crew that CDC believes were
exposed to co-traveler infected with a
communicable disease of public health
concern.
Stopping a communicable disease
outbreak—whether it is naturally
occurring or intentionally caused—
requires the use of the most rapid and
effective public health tools available.
Basic public health practices, such as
collaborating with airlines in the
identification and notification of
potentially exposed contacts, are critical
tools in the fight against the
introduction, transmission, and spread
of communicable diseases in the United
States.
The collection of comprehensive,
pertinent contact information enables
Quarantine Public Health Officers in
CDC’s Division of Global Migration and
Quarantine (DGMQ) to notify state and
local health departments in order for
them to make contact with individuals
who may have been exposed to a
contagious person during travel and
identify appropriate next steps.
In the event that there is a confirmed
case of communicable disease of public
health concern aboard an aircraft or
ship, CDC collects manifest information
for those passengers and crew at risk for
exposure. This specific manifest
information collection differs depending
on the communicable disease that is
confirmed during air or maritime travel.
CDC then uses this passenger and crew
manifest information to coordinate with
state and local health departments so
they can follow-up with residents who
live or are currently located in their
jurisdiction. In general, state and local
health departments are responsible for
the contact investigations. In rare cases,
CDC may use the manifest data to
perform the contact investigation
directly. In either case, CDC works with
state and local health departments to
ensure individuals are contacted and
provided appropriate public health
follow-up.
CDC estimates that for each traveler
manifest ordered, airlines require
approximately six hours to review the
order, search their records, and send
those records to CDC. There is no cost
to respondents other than their time
[FR Doc. 2016–265 Filed 1–8–16; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014
18:17 Jan 08, 2016
Jkt 238001
[30Day–16–16BM]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Airline and Maritime Conveyance
Manifest Orders—Existing Information
Collection in use without an OMB
Control Number—Division of Global
Migration and Quarantine, National
Center for Emerging Zoonotic and
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
E:\FR\FM\11JAN1.SGM
11JAN1
]]>Agencies
[Federal Register Volume 81, Number 6 (Monday, January 11, 2016)]
[Notices]
[Pages 1191-1192]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-265]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Board of Scientific Counselors, National Center for Injury
Prevention and Control, (BSC, NCIPC)
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces, the following meeting of the aforementioned
committee:
Time and Date: 9:00 a.m.-3:00 p.m., EST, January 28, 2016 (OPEN).
Public Comment Time and Date: 1:00 p.m.-2:30 p.m.*, EST, January
28, 2016.
* Please note that the public comment period ends at the time
indicated above or following the last call for comments, whichever is
earlier. Members of the public who want to submit comments must pre-
register by January 18, 2016 to opioidsguidelines@cdc.gov. All requests
must contain the name, address, email address, organizational
affiliation of the speaker, and the topic being addressed with
accompanying written comments. Written comments should be limited to
one page single spaced with 1 inch margins.
Members of the public must indicate at pre-registration whether
they would like to deliver oral remarks in addition to written comment.
Comments may be delivered in person or by phone and will be assigned on
a first come-first served basis until all time slots are filled.
Speakers providing public comment must call in or be present at the
beginning of the public comment period. All public comments will be
limited to two minutes per speaker. Since the number of time slots is
limited, it is requested that each organization register one speaker to
represent their organization. Both oral and written comments will be
included in the official record of the meeting.
Place: Centers for Disease Control and Prevention, Building 21,
Auditorium B-3, 1600 Clifton Road NE., Atlanta, GA 30329.
Audio Conference toll-free dial-in Number: 1-888-469-1243,
Participant Code: 4709506, TTY accessible link: https://www.captionedtext.com/client/event.aspx?CustomerID=1891&EventID=2812716.
CDC encourages participation by persons with disabilities. Captions
and participation by persons with communications challenges will be
available online via Relay Conference Captioning. To view the online
captions at the start time of the event, please login for captioning at
https://www.captionedtext.com/client/event.aspx?CustomerID=1891&EventID=2812716.
Requests for accommodations, questions, or comments on
accessibility (Section 508) compliance may be directed to Tonia
Lindley, imx9@cdc.gov.
Status: The meeting as designated above will be open to the public
limited only by the space available. The meeting room will accommodate
up to 200 people. See instructions above regarding pre-registration and
delivering public comment.
Purpose: The Board will: (1) Conduct, encourage, cooperate with,
and assist other appropriate public health authorities, scientific
institutions, and scientists in the conduct of research,
investigations, experiments, demonstrations, and studies relating to
the causes, diagnosis, treatment, control, and prevention of physical
and mental diseases, and other impairments; (2) assist States and their
political subdivisions in preventing and suppressing communicable and
non-communicable diseases and other preventable conditions and in
promoting health and well-being; and (3) conduct and assist in research
and control activities related to injury.
The Board of Scientific Counselors makes recommendations regarding
policies, strategies, objectives, and priorities; and reviews progress
toward injury prevention goals and provides
[[Page 1192]]
evidence in injury prevention-related research and programs. The Board
also provides advice on the appropriate balance of intramural and
extramural research, the structure, progress and performance of
intramural programs. The Board is designed to provide guidance on
extramural scientific program matters, including the: (1) Review of
extramural research concepts for funding opportunity announcements; (2)
conduct of Secondary Peer Review of extramural research grants,
cooperative agreements, and contracts applications received in response
to the funding opportunity announcements as it relates to the Center's
programmatic balance and mission; (3) submission of secondary review
recommendations to the Center Director of applications to be considered
for funding support; (4) review of research portfolios, and (5) review
of program proposals.
Matters for Discussion: The Board of Scientific Counselors will
discuss the draft recommendations in the CDC Guideline for Prescribing
Opioids for Chronic Pain (Guideline), as well as observations
formulated in the Opioid Guideline Workgroup Report. There will be 90
minutes allotted for public comments at the end of the session. See
above instructions on pre-registration for public comment. A transcript
of the meeting and public comments received at the meeting will be
posted to the docket at www.regulations.gov (Docket No. CDC-2015-0112).
Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Arlene Greenspan, Dr.P.H.,
M.P.H., P.T. Associate Director for Science, NCIPC, CDC, 4770 Buford
Highway NE., Mailstop F-63, Atlanta, GA 30341, Telephone (770) 488-
4696; Email opioidsguidelines@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2016-265 Filed 1-8-16; 8:45 am]
BILLING CODE 4163-18-P
